Thursday, June 01, 2017 8:11:44 AM
Click For Today's PR
Pre-Clinical Study to Determine the Effectiveness of the Company's Non-Invasive Medical Device in Preventing and Reversing Renal Inflammation and Fibrosis
LOS ANGELES, CA--(Marketwired - Jun 1, 2017) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease.
The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
The Company's Immunotronics™ platform is a non-invasive electroceutical device that harnesses magnetically-induced electrical field pathways in cells and organs to illicit an anti-inflammatory response in tissues and organs.
"Several kidney diseases have a strong inflammatory component and our aim is to demonstrate the anti-inflammatory and anti-fibrotic properties of our non-invasive electroceutical technology. Reversing inflammation in the kidneys that can cause injury, fibrosis and ultimately end-stage renal disease would represent a truly game changing application of bioelectronic medicine," stated Mr. Collier.
"We not only believe that bioelectronic medicine is the future but that our non-invasive electromagnetic approach will be the standard for treating vital organs," concluded Mr. Collier.
About Kidney Disease:
More than 31 million people in the United States are currently living with chronic kidney disease (CKD), according to the American Kidney Fund. Diabetes and high blood pressure are the most common causes of kidney disease.
Chronic kidney disease means lasting damage to the kidneys that can get worse over time and in cases where the damage is severe, it can lead to kidney failure, also known as end-stage renal disease. If the kidneys fail the only option for patients is a kidney transplant or dialysis.
According to the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), the five-year survival rate for dialysis patients is only 35.8%, in comparison to a five-year survival rate of 85.5% for transplant patients.
However, there are currently 100,791 people waiting for a kidney transplant, according to the National Kidney Foundation. This severe donor kidney shortage means that the median wait time for a patient's first kidney transplant is 3.6 years.
On average, over 3,000 new patients are added to the kidney waiting list each month and 13 people die each day while waiting for a life-saving kidney transplant.
A significant rise in the pool of patients suffering from CKD, particularly the rising number of elderly people prone to a variety of diseases, such as diabetes, cardiovascular disorders and neurological conditions that affect the kidneys severely will grow the demand for CKD treatments.
The market for chronic kidney disease (CKD) drugs is estimated to reach $15.8 billion by 2024, according to Transparency Market Research.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices.
The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM